Financial Enhancement Group’s CareDx CDNA Stock Holding History

Financial Enhancement Group’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21,213	Closed	-$669K	–	280
2019 Q1	$669K	Buy	+21,213	New	+$618K	0.2%	58

Other funds holding CDNA

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Financial Enhancement Group's CDNA Position: Q2 2019 in Review

Financial Enhancement Group sold out of CareDx (CDNA) in Q2 2019, closing a stake of 21,213 shares — an estimated $669K sold.

Financial Enhancement Group first reported a position in CDNA in Q1 2019 and held it in 1 quarter. The position peaked at $669K in Q1 2019. 182 funds tracked by Wall St. Rank hold CDNA as of Q2 2019.

Financial Enhancement Group reported no remaining CareDx position as of Q2 2019 after selling out during the quarter.
Financial Enhancement Group sold 21,213 CareDx shares in Q2 2019, an estimated $669K.
Financial Enhancement Group first reported a position in CareDx in Q1 2019 and held it in 1 quarter.
Financial Enhancement Group's CareDx position peaked at $669K in Q1 2019.
182 funds tracked by Wall St. Rank held CareDx as of Q2 2019.

Based on Financial Enhancement Group's 13F filing for Q2 2019, filed 6 Aug 2019.